Panion’s presentation at the investor meeting 14. December 2018

The CEO of Panion, Anja Holm, presented the progress and the plans for the company’s development at the investor meeting held at Mangold offices in relation with the current share issue.

Panion’s epilepsy project has just started the clinical phase with a pilot study in dogs.

Link to presentation: http://panion-animalhealth.com/2/wp-content/uploads/2018/12/Panion_20181214Stockholm.pdf

Link to emission-page: http://panion-animalhealth.com/emission/

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.